Boron therapy takes aim at deadly brain tumors
NCT ID NCT07003139
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a treatment called boron neutron capture therapy (BNCT) for people with malignant brain tumors. It uses a special boron compound (B10 L-BPA) that is injected and then activated by a neutron beam to kill cancer cells. The study will enroll 10 adults with grade 3 or 4 brain tumors to see if the treatment is safe and can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- B10 L-BPA (a boron-containing compound)
- What this could lead to
- If successful, this could offer a new treatment option for malignant brain tumors that are hard to treat with standard therapies.
- What could go wrong
- This is an early-phase trial with only 10 participants, so results may not apply to everyone. The therapy requires special equipment and may cause side effects like swelling or fatigue.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT BRAIN TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
China Medical University Hospital
RECRUITINGTaichung, 40447, Taiwan
-
China Medical University Hsinchu Hospital
RECRUITINGHsinchu, 302, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.